Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J’s Natrecor Out Of Medicare For Chronic Heart Failure

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS’ final national coverage determination does not change contractor discretion to cover other off-label uses.

You may also be interested in...

CMS Proposes To Cover J&J's Natrecor For Labeled Indication Only

CMS' proposed national coverage determination would not provide Medicare coverage of nesiritide for chronic heart failure.

Scios Overhauls Natrecor Physician Promotion

The Johnson & Johnson subsidiary's program for its congestive heart failure agent includes sales force training and new promotional materials that reflect expert panel recommendations on nesiritide use.

India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs

Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts